
Anabolic Research Pillar
Growth Hormone Secretagogues: Pulsatile GH, Body Composition, and the GHRH/GHRP Axis
Growth hormone (GH) is one of the most-studied hormones in metabolic and anabolic biology, but exogenous recombinant GH (somatropin) suppresses the hypothalamic-pituitary axis and shuts down endogenous production. The research field that emerged from this constraint focuses on growth-hormone secretagogues — peptides that drive the pituitary to release the body's own GH in physiological pulses, preserving feedback loops and circadian patterning.
Two mechanistically distinct classes drive secretagogue research. GHRH analogs (Sermorelin, Tesamorelin, CJC-1295) bind the GHRH receptor on somatotrophs and amplify natural GH release. GHRPs (Ipamorelin, Hexarelin, GHRP-6) bind the ghrelin/GHS-R1a receptor and trigger a separate GH pulse. Published endocrine studies that examined GHRH and GHRP signaling together reported a synergistic — not merely additive — GH response; this reflects the two-receptor mechanism and is described here as a mechanistic finding, not a recommendation.
GHRH vs GHRP: two receptors, one outcome
The GHRH receptor lives on the somatotroph cells of the anterior pituitary and responds to natural GHRH (44-amino-acid endogenous peptide) and engineered analogs. Sermorelin (the truncated 1–29 fragment) and Mod GRF 1-29 / CJC-1295 (a Mod GRF 1-29 with or without the DAC bonding extension that prolongs half-life) all bind here. They reset GH amplitude during the body's own natural pulses — they do not create new pulses, they make the existing ones bigger.
The GHS-R1a (ghrelin receptor) is a separate receptor expressed on the same somatotrophs plus hypothalamic feeding centers. GHRPs (Ipamorelin, Hexarelin, GHRP-6, GHRP-2) bind here. They CREATE new GH pulses by mimicking ghrelin — the natural orexigenic hormone that drives GH release alongside the GHRH cycle. Hexarelin and GHRP-6 also have measurable cross-receptor effects (cortisol elevation, prolactin elevation) that the cleaner GHRPs (Ipamorelin) avoid.
DAC vs no-DAC: half-life is a feature, not a bug
The "DAC" suffix on CJC-1295 refers to a Drug Affinity Complex — a small molecular addition that binds the peptide to serum albumin in circulation, extending half-life from ~30 minutes to ~7 days. CJC-1295 DAC produces a continuous, elevated GH "bleed" rather than discrete pulses; CJC-1295 no-DAC (Mod GRF 1-29) produces a sharp pulse that decays within hours and matches the natural GH cycle.
Readouts of pulsatile physiology — IGF-1 dynamics, sleep-architecture effects, body-composition change over weeks to months — reflect the short-pulse profile of the no-DAC form. Continuous elevation (CJC-1295 DAC) produces different downstream signaling and is more analogous to recombinant GH than to physiological GH-pulse augmentation, so results from the two forms are not directly comparable.
Tesamorelin sits in a middle position. Its parent-compound half-life is ~30 minutes, but its IGF-1 effects are sustained, and it is FDA-approved as a prescription medicine for excess abdominal fat in adults with HIV-associated lipodystrophy. Because of that approval, it has human clinical data on body-composition endpoints that most other secretagogues lack.
Interactions relevant to published data
Published endocrine literature describes several interactions that affect how secretagogue data is interpreted: GHS-R1a is the ghrelin receptor, so ghrelin-pathway appetite readouts overlap with GHRP activity; glucocorticoids blunt GH release; and IGF-1 modulates thyroid binding globulin levels, which affects thyroid hormone measurements.
Frequently Asked Questions
How do secretagogues differ from recombinant GH in research?
Secretagogues preserve the natural pulsatile pattern of GH release and the hypothalamic-pituitary feedback loop. Exogenous recombinant GH suppresses endogenous production and produces continuous elevation that researchers and clinicians have linked to receptor desensitization and metabolic side effects. The secretagogue research class exists specifically to drive the body's own pulses without breaking the regulatory architecture.
How do CJC-1295 DAC and no-DAC differ in published research?
In the GH-release profile. No-DAC (Mod GRF 1-29) produces a short pulse that matches the natural GH pattern and is the form used in pulsatile-physiology research. DAC binds serum albumin and produces continuous IGF-1 elevation — more analogous to recombinant GH, with different downstream signaling. Results from the two forms are not directly comparable.
How do the GHRPs differ in receptor selectivity?
Published comparative work reports different off-target profiles: GHRP-6 raises cortisol and prolactin, GHRP-2 raises prolactin, and Hexarelin is associated with GHS-R1a receptor desensitization over repeated exposure. Ipamorelin shows the most selective profile in that work — GH-pulse activity with minimal reported off-target hormonal effects.
Research products for this pillar
Muscle Growth →All compounds referenced are chemical reagents for laboratory analysis. See our Terms & Conditions.







